Non-Oncology Biopharmaceuticals Market to hit US$ 313.70B by 2033, driven by rising demand for biologics, biosimilars & gene therapies for rare diseases. Non-Oncology Biopharmaceuticals Market to hit ...

Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through multiple mechanisms India represents a key ...

A Buckinghamshire mother has urged people to sign up to a UK-wide health and care research registry after joining a trial ...

Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...